Company Profile
Prothena Stock Price, News & Catalysts
- Ticker:
- PRTA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Ireland
Stock performance
9.39 USD (-0.63%)
Close
Last updated: August 24, 2026
481M USD
Market cap
Why the stock is moving
As of Aug 24, 2026, PRTA closed down 0.63% at $9.39. No new same-company headline was identified in the current news window.
Company overview
Business overview
Prothena is a neuroscience and protein-dysregulation biotechnology company focused on rare neurodegenerative and amyloid-related diseases. Its pipeline is aimed at high-unmet-need areas where clinical data can quickly change the market’s view.
Geographic Base and Sector Classification
Headquartered in Ireland and listed on NASDAQ, Prothena has a transatlantic biotech profile. It sits in neuroscience and protein-misfolding biology.
Business Model Characteristics
The company’s value is driven by clinical readouts, partnership activity, and the ability to translate deep biology into differentiated programs. Investors watch safety, efficacy, and the durability of its lead scientific hypotheses.
Position Within the Biotechnology Landscape
Prothena sits in the high-risk, high-catalyst neuroscience niche of biotech. The stock can move sharply around data because the programs are small in number but potentially large in impact.
Future catalysts
- Prothena's catalysts are PRX012 and the tau/amyloid program cadence, with any next clinical update helping decide whether the neuroscience story still has real optionality. The market wants human data that can support a longer development path rather than another broad platform pitch.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Prothena (PRTA)?
Prothena (PRTA) most recently closed at 9.39 USD, a -0.63% move versus the previous session.
What is the market cap of Prothena (PRTA)?
Prothena currently has a market capitalization of 481M USD on BioPharmSignal.
What does Prothena do?
Prothena is a neuroscience and protein-dysregulation biotechnology company focused on rare neurodegenerative and amyloid-related diseases. Its pipeline is aimed at high-unmet-need areas where clinical data can quickly change the market’s view.
On which exchange is PRTA stock listed?
Prothena (PRTA) is associated with NASDAQ, Ireland, Biopharma.
What is Prothena?
Prothena's catalysts are PRX012 and the tau/amyloid program cadence, with any next clinical update helping decide whether the neuroscience story still has real optionality.
Which conditions is Prothena targeting with Prothena?
Prothena is associated with neuroscience based on its company overview and current catalyst commentary.
How does Prothena describe recent progress with Prothena?
Prothena's catalysts are PRX012 and the tau/amyloid program cadence, with any next clinical update helping decide whether the neuroscience story still has real optionality.
What is PRX012?
Prothena's catalysts are PRX012 and the tau/amyloid program cadence, with any next clinical update helping decide whether the neuroscience story still has real optionality.